Poseida Therapeutics, Inc. Common Stock
PSTX
PSTX was delisted on the 7th of January, 2025.
101 hedge funds and large institutions have $136M invested in Poseida Therapeutics, Inc. Common Stock in 2023 Q1 according to their latest regulatory filings, with 28 funds opening new positions, 35 increasing their positions, 22 reducing their positions, and 15 closing their positions.
507% more call options, than puts
Call options by funds: $182K | Put options by funds: $30K
87% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 15
59% more repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 22
13% more funds holding
Funds holding: 89 → 101 (+12)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
40% less capital invested
Capital invested by funds: $226M → $136M (-$90.2M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Acadian Asset Management
Boston,
Massachusetts
|
+$4.87M |
| 2 |
Dimensional Fund Advisors
Austin,
Texas
|
+$2.86M |
| 3 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
+$2.75M |
| 4 |
Two Sigma Investments
New York
|
+$2.49M |
| 5 |
Renaissance Technologies
New York
|
+$2.44M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$8.39M |
| 2 |
PBA
Paradigm Biocapital Advisors
New York
|
-$8.17M |
| 3 |
Millennium Management
New York
|
-$4.02M |
| 4 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$1.62M |
| 5 |
Invesco
Atlanta,
Georgia
|
-$1.54M |
PSTX Hedge Fund Activity: Q1 2023 in Review
101 of the 6,276 institutional investors tracked by Wall St. Rank reported a position in Poseida Therapeutics, Inc. Common Stock (PSTX) for Q1 2023, worth a combined $136M — down 40% from $226M a quarter earlier.
Buyers outnumbered sellers: 28 funds opened new PSTX positions and 15 closed out — a net gain of 13 holders — while 35 added to existing stakes and 22 trimmed.
The largest buyer was Acadian Asset Management, adding an estimated $4.87M. The largest seller was Wellington Management Group, cutting an estimated $8.39M.
- 101 institutional investors held Poseida Therapeutics, Inc. Common Stock (PSTX) as of Q1 2023, up from 89 in Q4 2022.
- Funds reported $136M of Poseida Therapeutics, Inc. Common Stock stock for Q1 2023, down 40% quarter-over-quarter.
- 28 funds opened new Poseida Therapeutics, Inc. Common Stock positions in Q1 2023 and 15 closed out, a net change of +13 holders.
- The largest Poseida Therapeutics, Inc. Common Stock buyer in Q1 2023 was Acadian Asset Management, an estimated $4.87M added.
- The largest Poseida Therapeutics, Inc. Common Stock seller in Q1 2023 was Wellington Management Group, an estimated $8.39M sold.
Based on aggregated 13F filings for Q1 2023.